This communication is neither an offer to sell, nor a solicitation of an offer to purchase, any security
Lilly started selling Foundayo in the US earlier this month and is locked in a marketing battle with Novo Nordisk, whose oral formulation of GLP-1 drug Wegovy (semaglutide) was launched earlier this year
Nooms program starts at 0.2 milligrams of semaglutide and goes up to a maximum of 0.6 milligrams, or one-quarter of the standard maximum dose
CD36 plays a significant role in the pathogenesis of atherosclerosis by serving as a highly specific receptor for oxidized phospholipids prevalent in ox-LDL
Orforglipron also reduced non-HDL cholesterol, triglycerides and systolic blood pressure and decreased high-sensitivity C-reactive protein by 47.7%
Individuals with any of the following conditions should consult with their healthcare provider before use and may not be eligible for treatment: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) Known hypersensitivity to GLP-1 or GLP-1/GIP medications or any formulation components, including additives such as vitamin B12 or cobalt Pregnancy or plans to become pregnant (therapy should be discontinued at least two months prior to planned pregnancy) Diabetic ketoacidosis (DKA) or type 1 diabetes Severe gastrointestinal disease (including gastroparesis or active inflammatory bowel disease) Severe cardiovascular disease (including unstable coronary artery disease or heart failure) Recent bariatric or gastrointestinal surgery within the past six months Active cancer currently undergoing chemotherapy or radiation treatment This list is not comprehensive
